IISc researchers find antibiotic combination to reverse drug resistance in TB
IISc researchers find antibiotic combination to reverse drug resistance in TB
- ✓IISc researchers find antibiotic combination to reverse drug resistance in TB
- ✓Together, they cut bacterial load about 10-fold in both lungs and spleen.
- ✓Civic Domain: Categorized under health public notices.
NewsIndia NewsIISc researchers find antibiotic combination to reverse drug resistance in TB IISc researchers find antibiotic combination to reverse drug resistance in TB Colonies of M. tuberculosis growing in an agar plate | Pic Credit: IISc BENGALURU: Researchers from the Indian Institute of Science (IISc) have identified an antibiotic combination that can reverse resistance to isoniazid, a frontline drug for tuberculosis (TB), in laboratory tests and in mice.
TB remains one of the world's most persistent health challenges.The study, titled “Vancomycin rescues sensitivity to isoniazid in clinical isolates of drug-resistant Mycobacterium tuberculosis,” has been published in Microbiology Spectrum.The team from IISc’s department of biochemistry paired isoniazid with vancomycin.
The combination sharply reduced bacterial growth in clinical isolates from drug-resistant TB patients and lowered bacterial load in mice infected with multidrug-resistant (MDR) ‘M tuberculosis’, according to IISc. Authors of the study: (left to right) Nagasuma Chandra (corresponding author), Amit Singh (co-author), Sukriti Pal (co-author), Shalini Birua (co-author) | Pic Credit: IISc Isoniazid is a prodrug, which means a bacterial enzyme must activate it before it can work.
Mutations in certain genes can block this activation, letting the bacteria survive. Growing resistance has become a major challenge in TB treatment.Vancomycin, used against several bacterial infections, normally struggles to cross the highly impermeable cell wall of M.
tuberculosis. The researchers report that when the two drugs are given together, the cell wall loses integrity, allowing vancomycin to enter and kill the bacteria. The team tested isolates from sputum samples of patients with drug-resistant TB, working with the National Tuberculosis Institute, Bengaluru.
They showed a broad range of isoniazid resistance, allowing the team to test the combination against different resistance mechanisms.The combination substantially outperformed either drug alone. Most isolates showed more than 90% reduction in bacterial growth, including isoniazid-resistant and MDR strains.The team then tested the combination in mice infected with MDR M.
tuberculosis, in collaboration with Amit Singh, professor at IISc's Centre for Infectious Disease Research and department of microbiology and cell biology.After 10 days of treatment, neither drug alone significantly reduced bacterial burden.
Together, they cut bacterial load about 10-fold in both lungs and spleen. Lung tissue also showed fewer granulomas, inflammatory structures that form as the body tries to contain TB infection.“Isoniazid resistance poses a major challenge in the treatment of TB.
To tackle this problem, we started exploring ways to rescue the drug by reversing resistance,” said Nagasuma Chandra, professor at the department of biochemistry and corresponding author of the study.Join conversation InsightfulAgreeDisagreeSkepticalConcerningPromisingWorth ReadingBig Development “Although several antibiotic combinations are available for TB treatment, we continue to face challenges due to drug-resistance.
Our study identifies a drug treatment strategy that can reverse resistance to isoniazid, an otherwise highly effective antibiotic,” said Sukriti Pal, a PhD student and the study's first author.The study's authors include Pal, Shalini Birua, Singh and Chandra, among others.
The combination is not yet ready for use in patients. The team is working to advance it towards clinical trials.“Before the combination can be considered for use in patients, its safety and efficacy need to be studied much more extensively.
Clinical trials need to be conducted on drug-resistant TB cases,” Pal said. Get the latest India News and Live updates. Download the TOI app. Chethan Kumar is a Senior Assistant Editor with the Times of India. Aside from specialising in Space & Science, he has reported extensively on varied topics, with special focus on defence, policy and data stories.
He has covered multiple elections, too. As a young democracy grows out of adolescence, Chethan feels, there are reels of tales emerging which need to be captured. To do this, he alternates between the mundane goings-on of the Common Man and the wonder-filled worlds of scientists and scamsters, politicians and soldiers.
In a career spanning nearly 18 years, he has reported from multiple datelines — Houston, Florida, Kochi, Hyderabad, Chennai, Sriharikota (AP), NH-1 (J&K Highway), New Delhi, Ahmedabad, Raichur, Bhatkal, Mysuru, Chamarajanagar, to name a few — but is based out of Bengaluru, India’s science capital that also hosts the ISRO HQ.
'Don't Lecture India': Meloni Ally BLASTS Italian Leader’s 'Vote Thieves' Remark At Congress Event 'New Team, New Strategy': BJP Gives Roles To Former AAP MPs In Punjab ELECTIONS WITH TOI | Why Are Donors Abandoning Congress?
The 75% Funding Slump Uttarakhand Cong MLA Harish Dhami Creates Ruckus After Being Denied Speech in CM's Presence China Border ‘More Alive’: Jaishankar Reveals India’s Military And Infrastructure Push After Galwan China Border ‘More Alive’: Jaishankar Reveals India’s Military And Infrastructure Push After Galwan Pakistan Sends Experienced Minister To Delhi: Is A New India-Pakistan Diplomatic Chapter Beginning?
- •Aspirants and citizens are advised to monitor official notices and circulars issued by Times of India National.
- •Verify all prescribed eligibility criteria, cutoff dates, and authenticated document requirements prior to formal submissions.
- •Track connected examination timetables, vacancy advisories, and administrative gazettes on SuchnaSetu.
| Issuing Authority | Times of India National |
|---|---|
| Topic Category | HEALTH |
| Jurisdiction | All India / National |
| Publication Date | 16 November 2026 |